What is Amphastar Pharmaceuticals's D&A?

Amphastar Pharmaceuticals (AMPH) reported D&A of $8.08M in Q1 2026.

How has Amphastar Pharmaceuticals's D&A changed year-over-year?

Amphastar Pharmaceuticals's D&A increased by 9.6% year-over-year, from $7.37M to $8.08M.

What is the long-term trend for Amphastar Pharmaceuticals's D&A?

Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's D&A has grown at a 9.3% compound annual growth rate (CAGR), from $22.2M to $31.65M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Amphastar Pharmaceuticals AMPH D&A

D&A at other companies

PfizerPFE

$1.61B-0.3%

Halozyme TherapeuticsHALO

$4.22M+57.1%

ViatrisVTRS

$676.1M+1.7%

Opko HealthOPK

$22.2M-5.5%

AptarGroupATR

$64.31M+17.1%

ARS Pharmaceuticals, Inc.SPRY

$397K+41.8%

Segments

By segment

See full

Pharmaceutical Products$13.61M—

Other financials

Income statement

See full

Revenue$171.2M+0.4%

Gross profit$70.3M-17.5%

Operating income$13.6M-63.5%

Net income$6.4M-74.6%

EPS (diluted)$0.14-72.5%

Balance sheet

See full

Cash & equivalents$170.9M-6.5%

Total debt$686.6M+5.2%

Total equity$445.5M—

Total assets$1.6B+1.3%

Cash flow

See full

Operating cash flow$47.8M+36.4%

CapEx$9.5M-11.1%

Free cash flow$38.3M+57.2%

Valuation

See full

Market cap$926.83M-19.9%

Enterprise value$1.44B-11.3%

P/E11.7×+3.5×

P/S1.3×-0.3×

Profitability

See full

Gross margin47.3%-3.2pp

Operating margin16.2%-10.4pp

Net margin11%-8.4pp

FCF margin18.8%-1.8pp

Returns & leverage

See full

Return on equity14.7%—

Debt / equity0.2×—

Current ratio3.9×+0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amphastar Pharmaceuticals's D&A?: Amphastar Pharmaceuticals (AMPH) reported D&A of $8.08M in Q1 2026.
How has Amphastar Pharmaceuticals's D&A changed year-over-year?: Amphastar Pharmaceuticals's D&A increased by 9.6% year-over-year, from $7.37M to $8.08M.
What is the long-term trend for Amphastar Pharmaceuticals's D&A?: Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's D&A has grown at a 9.3% compound annual growth rate (CAGR), from $22.2M to $31.65M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.